Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | CPB1 | P15086 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28017484 | 0.87 | MEN1 (0.43) | KMT2AMEN1SLC18A3KCNH2HTR2A | |
| SCHEMBL27758338 | 0.86 | HSD11B1 (0.57) | KMT2AHTR2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL28021721 | 0.86 | MGLL (0.57) | KMT2AMEN1MGLLHSD11B1 | |
| SCHEMBL27991279 | 0.86 | MGLL (0.51) | KMT2AMEN1SLC18A3MGLLHSD11B1 | |
| SCHEMBL27689722 | 0.85 | ALDH1A1 (0.49) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL27751800 | 0.85 | ALDH1A1 (0.49) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL27968799 | 0.84 | MGLL (0.55) | KMT2AMEN1MGLLHSD11B1ALDH1A1 | |
| SCHEMBL27968804 | 0.83 | HSD11B1 (0.56) | KMT2AMEN1MGLLHSD11B1ALDH1A1 | |
| SCHEMBL27832420 | 0.82 | CYP2D6 (0.41) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL2573870 | 0.81 | KMT2A (0.59) | KMT2AMEN1SLC18A3KCNH2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105073729-A | Phenyl-linked quinolinyl modulators of ROR γ t | JANSSEN PHARMACEUTICA NV | 2015-11-18 | — | — | CN | disclosed |
| CN-104781238-A | Pyrazole carboxamide compounds, compositions and methods of use | HOFFMANN LA ROCHE | 2015-07-15 | — | — | CN | disclosed |
| CN-101443312-B | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions | FAES FARMA SA | 2011-07-06 | — | — | CN | disclosed |
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | US | disclosed |
| US-7615555-B2 | Piperidine derivatives as modulators of chemokine receptor CCR5 | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| CN-101443312-A | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions | FAES FARMA SA (ES) | 2009-05-27 | — | — | CN | disclosed |
| CN-100484524-C | Thiazolidine carboxamide derivatives as modulators of the prostaglandin receptor | APPLIED RESEARCH SYSTEMS (CH) | 2009-05-06 | — | — | CN | disclosed |
| US-20070167442-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | US | disclosed |
| US-20070161646-A1 | Piperidine Derivatives and Their Use as Modulators of Chemokine Receptor Activity (Especially CCR5) | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| US-7192973-B2 | Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5) | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| EP-1742934-A2 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005101989-A2 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | WO | disclosed |
| CN-1655780-A | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor | APPLIED RESEARCH SYSTEMS (AN) | 2005-08-17 | — | — | CN | disclosed |
| US-20040267016-A1 | Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) | ASTRAZENECA AB (SE) | 2004-12-30 | — | — | US | disclosed |
| EP-1448548-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | AstraZeneca AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003042205-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | CCR5, CCR2, CXCR3 | KMT2A 4652/4885MEN1 4874/4885SLC18A3 567/4885 |
| US-20040267016-A1 | Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) | CCR5, CCR2, CCR1 | KMT2A 4487/4885MEN1 4759/4885SLC18A3 883/4885 |
| US-20070161646-A1 | Piperidine Derivatives and Their Use as Modulators of Chemokine Receptor Activity (Especially CCR5) | CCR5, CCR2, CCL5 | KMT2A 4465/4885MEN1 4828/4885SLC18A3 795/4885 |
| US-20070167442-A1 | Chemical compounds | CCR5, CXCR3, CX3CR1 | KMT2A 4701/4885MEN1 4165/4885SLC18A3 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.